Web of Science: 21 citations, Scopus: 21 citations, Google Scholar: citations,
Safety and pharmacokinetic profile of fixed-dose ivermectin with an innovative 18mg tablet in healthy adult volunteers
Muñoz, Jose (Barcelona Institute for Global Health (ISGlobal))
Ballester, Maria Rosa (Institut d'Investigació Biomèdica Sant Pau)
Antonijoan Arbós, Rosa Ma. (Rosa María) (Universitat Autònoma de Barcelona. Departament de Farmacoloia, Terapèutic i Toxicologia)
Gich Saladich, Ignasi (Universitat Autònoma de Barcelona. Departament de Farmacoloia, Terapèutic i Toxicologia)
Rodríguez, Montse (Institut d'Investigació Biomèdica Sant Pau)
Colli, Enrico (ExeltisPharma, Chemo group. Madrid, Spain)
Gold, Silvia (Fundacion Mundo Sano, Buenos Aires, Argentina)
Krolewiecki, Alejandro J. (Instituto de Investigaciones en Enfermedades Tropicales, Universidad Nacional de Salta/CONICET, Oran, Argentina)
Universitat Autònoma de Barcelona

Date: 2018
Abstract: ClinicalTrials. gov . Current efforts for the control of poverty-related diseases provide drug treatments through mass drug administration (MDA) as a key component. Ivermectin is an antiparasitary drug which has been used to fight some of these diseases, and millions of treatments have been distributed with a favorable toxicity profile. The dosing strategy of ivermectin is based on weight, which in view of the safety characteristics of ivermectin might not be necessary, while a fix dosing strategy might improve logistics and access to the drug to those who need it. This study was conducted in healthy adult volunteers in which we compared 3 treatment regimens: the weight-based reference standard versus 2 experimental regimens of fix-dose 18 and 36 mg using 18 mg tablets. All 54 volunteers received the 3 treatments sequentially. The results confirmed that the fixed-dose regimen (both 18 mg and 36 mg) are as safe as the standard dosage and could justify the use of fix dosing regimens rather than the current weight based strategy.
Rights: Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. Creative Commons
Language: Anglès
Document: article ; recerca ; publishedVersion
Published in: PLoS neglected tropical diseases, Vol. 12 (january 2018) , ISSN 1935-2735

DOI: 10.1371/journal.pntd.0006020
PMID: 29346388

16 p, 1.9 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (scientific output) > Health sciences and biosciences > Institut d'Investigació Biomèdica Sant Pau
Articles > Research articles
Articles > Published articles

 Record created 2018-03-06, last modified 2021-02-18

   Favorit i Compartir